These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1075 related items for PubMed ID: 30326995

  • 1. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
    Patel C, Brotherton JM, Pillsbury A, Jayasinghe S, Donovan B, Macartney K, Marshall H.
    Euro Surveill; 2018 Oct; 23(41):. PubMed ID: 30326995
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study.
    Chow EPF, Machalek DA, Tabrizi SN, Danielewski JA, Fehler G, Bradshaw CS, Garland SM, Chen MY, Fairley CK.
    Lancet Infect Dis; 2017 Jan; 17(1):68-77. PubMed ID: 27282422
    [Abstract] [Full Text] [Related]

  • 4. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study.
    Chow EP, Danielewski JA, Fehler G, Tabrizi SN, Law MG, Bradshaw CS, Garland SM, Chen MY, Fairley CK.
    Lancet Infect Dis; 2015 Nov; 15(11):1314-23. PubMed ID: 26201300
    [Abstract] [Full Text] [Related]

  • 5. Declines in Prevalence of Human Papillomavirus Vaccine-Type Infection Among Females after Introduction of Vaccine - United States, 2003-2018.
    Rosenblum HG, Lewis RM, Gargano JW, Querec TD, Unger ER, Markowitz LE.
    MMWR Morb Mortal Wkly Rep; 2021 Mar 26; 70(12):415-420. PubMed ID: 33764964
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases.
    Diakite I, Nguyen S, Sabale U, Pavelyev A, Saxena K, Tajik AA, Wang W, Palmer C.
    J Med Econ; 2023 Mar 26; 26(1):1085-1098. PubMed ID: 37608730
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Potential impact of a nonavalent HPV vaccine on HPV related low-and high-grade cervical intraepithelial lesions: A referral hospital-based study in Sicily.
    Capra G, Giovannelli L, Matranga D, Bellavia C, Guarneri MF, Fasciana T, Scaduto G, Firenze A, Vassiliadis A, Perino A.
    Hum Vaccin Immunother; 2017 Aug 03; 13(8):1839-1843. PubMed ID: 28594305
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis.
    Drolet M, Bénard É, Boily MC, Ali H, Baandrup L, Bauer H, Beddows S, Brisson J, Brotherton JM, Cummings T, Donovan B, Fairley CK, Flagg EW, Johnson AM, Kahn JA, Kavanagh K, Kjaer SK, Kliewer EV, Lemieux-Mellouki P, Markowitz L, Mboup A, Mesher D, Niccolai L, Oliphant J, Pollock KG, Soldan K, Sonnenberg P, Tabrizi SN, Tanton C, Brisson M.
    Lancet Infect Dis; 2015 May 03; 15(5):565-80. PubMed ID: 25744474
    [Abstract] [Full Text] [Related]

  • 12. Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine.
    Zhang Z, Zhang J, Xia N, Zhao Q.
    Hum Vaccin Immunother; 2017 Oct 03; 13(10):2280-2291. PubMed ID: 28699820
    [Abstract] [Full Text] [Related]

  • 13. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER, Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices (ACIP).
    MMWR Recomm Rep; 2007 Mar 23; 56(RR-2):1-24. PubMed ID: 17380109
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience.
    Garland SM, Kjaer SK, Muñoz N, Block SL, Brown DR, DiNubile MJ, Lindsay BR, Kuter BJ, Perez G, Dominiak-Felden G, Saah AJ, Drury R, Das R, Velicer C.
    Clin Infect Dis; 2016 Aug 15; 63(4):519-27. PubMed ID: 27230391
    [Abstract] [Full Text] [Related]

  • 17. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.
    Drolet M, Bénard É, Pérez N, Brisson M, HPV Vaccination Impact Study Group.
    Lancet; 2019 Aug 10; 394(10197):497-509. PubMed ID: 31255301
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Human papilloma virus (HPV) prevalence upon HPV vaccination in Swedish youth: a review based on our findings 2008-2018, and perspectives on cancer prevention.
    Du J, Ährlund-Richter A, Näsman A, Dalianis T.
    Arch Gynecol Obstet; 2021 Feb 10; 303(2):329-335. PubMed ID: 33247317
    [Abstract] [Full Text] [Related]

  • 20. Prevalence of human papillomavirus in teenage heterosexual males following the implementation of female and male school-based vaccination in Australia: 2014-2017.
    Chow EPF, Tabrizi SN, Fairley CK, Wigan R, Machalek DA, Regan DG, Hocking JS, Garland SM, Cornall AM, Atchison S, Bradshaw CS, McNulty A, Owen L, Marshall L, Russell DB, Kaldor JM, Chen MY.
    Vaccine; 2019 Oct 31; 37(46):6907-6914. PubMed ID: 31562001
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.